

Y. Ikeura, et al
U.S.S.N. 09/807,337
Page 2

Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

- 1-3. (Cancelled).
4. (Presently Amended) ~~The A~~ base for a percutaneously absorbing preparation according to ~~claims 1 to 3~~, wherein styrene-isoprene-styrene block copolymer and/or polyisobutylene, softener and tackifier are essential components and hexylene glycol and 1-menthol are sorbafacients as the components of the base.
5. (Presently Amended) The base for a percutaneously absorbing preparation according to ~~claims 2 to claim 4~~, wherein 10-40% by weight of styrene-isoprene-styrene block copolymer, 2-10% by weight of polyisobutylene, 10-60% by weight of softener and 20-60% by weight of tackifier are essential components and 1-10% by weight of hexylene glycol and 0.1-7% by weight of 1-menthol are compounded therewith as the components of the base.
6. (Presently Amended) A percutaneously absorbing preparation according to ~~claims 4 to 5~~, wherein a pharmaceutical agent is contained as an effective ingredient in the base for a percutaneously absorbing preparation mentioned in claims 4 to 5.
7. (Presently Amended) The percutaneously absorbing preparation according to ~~claims 4 to claim 6~~, wherein the pharmaceutical agent is follicular hormone and/or luteinizing hormone.
8. (Original) The percutaneously absorbing preparation according to claim 7, wherein the

Y. Ikeura, et al
U.S.S.N. 09/807,337
Page 3

follicular hormone is estradiol or a derivative thereof and its compounding amount if 0.1-5% by weight.

9. (Original) The percutaneously absorbing preparation according to claim 7, wherein the luteinizing hormone is norethisterone, norethisterone acetate or a derivative thereof and its compounding amount is 0.5-10% by weight.